STOCKHOLM, Sweden, 2 March 2026
Avia Pharma AB (“Avia”), a Sweden‑based pharmaceutical company focusing on OTC products across Northern Europe, today announced that it has completed the acquisition of the Swedish consumer health company Allderma AB (“Allderma”). The transaction closed on 27 February 2026 and represents another important step in Avia’s strategy to expand its presence within medically positioned consumer health and dermatology.

STOCKHOLM, Sweden, 2 December 2025
Tolfer is a new iron supplement developed for people with increased iron needs who experience gastrointestinal discomfort from certain traditional iron salts, such as ferrous sulfate. The product is now being launched in Sweden and Finland by Avia Pharma, and is based on the patented IHAT™ technology (Iron Hydroxide Adipate Tartrate) – designed to mimic how iron from food is absorbed and to reduce stomach-related discomfort.

STOCKHOLM, Sweden, 9 June 2025
Avia Pharma is expanding its self-care portfolio with the launch of Oralmedic, a fast and effective treatment for mouth ulcers, across the Nordic region…

STOCKHOLM, Sweden, 14 March 2025
Avia Pharma has entered into an exclusive agreement with Nemysis Limited to introduce Tolfer, a next-generation iron supplement containing IHAT (Iron Hydroxide Adipate Tartrate), to the Nordic market…

STOCKHOLM, Sweden, 1 January 2025
Avia Pharma is announcing its official representation in the Nordics of Theramex, a global specialty pharmaceutical company that specializes in women’s health products…

STOCKHOLM, Sweden, 2 February 2024
Avia Pharma Holding AB (“Avia” or the “Company”) has completed the acquisition of Neubourg Skin Care GmbH (“Neubourg”), a leading German dermatology company, specialized in skin, foot and nail care…

STOCKHOLM, Sweden, 2 February 2024
During January, Avia Pharma Holding AB (“Avia” or the “Company”), welcomed Impilo AB as a new owner and partner to the co-founders…

STOCKHOLM, Sweden, 15 June 2023
Avia Pharma has today completed the acquisition of ACO Vitamin D water and will as the new marketing authorisation holder re-launch the pharmaceutical in the Swedish market in Q4 this year…

STOCKHOLM, Sweden, 1 February 2023
Avia Pharma is launching Nyvigan in Swedish pharmacies. Nyvigan (nystatin) is a combination treatment (pessaries + cream) for the treatment of vulvovaginal Candida…

STOCKHOLM, Sweden, 1 August 2022
Avia Pharma has today completed the acquisition of Unimedic’s Vitamin D oil.

STOCKHOLM, Sweden, 29 July 2022
Avia Pharma has today completed the acquisition of Allergika Pharma GmbH. The company has a turnover of close to 15 million EUR and is placed in Wolfratshausen, near Munich…

STOCKHOLM, Sweden, 1 April 2022 Avia Pharma has today completed the acquisition of Decem Pharma. Decem Pharma is a Finish pharmaceutical company with its own brands with strong market positions, such as Magnecit and Otocur. The acquisition of Decem Pharma is Avia Pharma’s first acquisition outside of Sweden and part

Following a strong sales increase in the current portfolio, Avia Pharma and Perrigo have deepened the relationship to also include Vectavir®, Vectatone®, Oralmedic® and Predictor®.

Avia Pharma appoints Mattias Wik as Business Unit Director Oncology/Urology.